Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Perindopril · 2 trials · 4 indications
spot urine samples
24 hour, day, and night systolic and diastolic blood pressure
1 month treatment adjustment 3 months of endpoint follow-up - M4 6 months of endpoint follow-up - M7 12 months of endpoint follow-up - M13
| Arm | Type | Description |
|---|---|---|
| Ramipril | ACTIVE_COMPARATOR | Maximal recommended dose of ramipril "Altace®" (10 mg/d) given as an active comparator for 12 week. |
| Perindopril | EXPERIMENTAL | Perindopril "Coversyl®" at maximal recommended dose (8 mg/d) as experimental therapy for 12 weeks. |
| Placebo (for perindopril) | PLACEBO_COMPARATOR | Sugar pill manufactued to mimic perindopril |
| Name | Type | Description |
|---|---|---|
| ramipril | DRUG | Comparison of two renin angiotensin aldosterone inhibitors |
| perindopril | DRUG | Comparison of two renin angiotensin aldosterone inhibitors |
Inclusion Criteria: * Type 2 Diabetes, * stable therapy with an ACEi or ARB for 8 weeks prior to screening period * blood pressure controlled to \< 130/80 mmHg Exclusion Criteria: * Pregnancy, * dual therapy with ACEi and ARB 8 weeks prior to screening * history of cough with ACEi * hypersensitiv...
Perindopril is used for essential hypertension and diabetes, specifically in the context of microalbuminuria. It is a small molecule cardiovascular drug being developed by Tango Therapeutics, Inc. (TNGX). Perindopril is currently in Phase 3 clinical development for these indications.
Perindopril is an angiotensin-converting enzyme (ACE) inhibitor. It works by inhibiting the ACE enzyme, which reduces the production of angiotensin II, a potent vasoconstrictor. This leads to vasodilation and lower blood pressure, making it effective for treating hypertension and related conditions.
Perindopril is being developed by Tango Therapeutics, Inc., a biopharmaceutical company listed on the NASDAQ under the ticker symbol TNGX. The company is conducting clinical trials to evaluate the drug's efficacy in treating essential hypertension and diabetes-related microalbuminuria.
Perindopril is in Phase 3 clinical development. It has completed two Phase 3 trials, one with 316 participants and another with 23 participants. The drug is investigational and has not been approved by regulatory authorities for the indications under study.
Perindopril has been studied in two completed Phase 3 trials. NCT00461903 evaluated its efficacy in preventing recurrence of atrial fibrillation in patients with essential hypertension, enrolling 316 participants. NCT02729441 compared Perindopril to Ramipril for persistence in microalbuminuria reduction in diabetic patients, enrolling 23 participants.
No, Perindopril is not the same as Ramipril. Both are ACE inhibitors, but they are distinct chemical entities. A clinical trial (NCT02729441) directly compared Perindopril to Ramipril for persistence in microalbuminuria reduction, indicating they are separate drugs with potentially different effects.